Poseida Therapeutics, Inc.
PSTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $303,022 | $381,135 | $423,420 | $640,648 |
| - Cash | $44,472 | $81,378 | $206,325 | $83,966 |
| + Debt | $85,423 | $88,752 | $61,198 | $59,315 |
| Enterprise Value | $343,973 | $388,509 | $278,293 | $615,997 |
| Revenue | $64,703 | $130,362 | $31 | $0 |
| % Growth | -50.4% | 417,217.1% | – | – |
| Gross Profit | -$92,069 | $125,190 | -$4,521 | -$2,586 |
| % Margin | -142.3% | 96% | -14,472% | – |
| EBITDA | -$109,038 | -$51,916 | -$117,064 | -$145,483 |
| % Margin | -168.5% | -39.8% | -374,748.7% | – |
| Net Income | -$123,430 | -$64,002 | $4,404 | $2,452 |
| % Margin | -190.8% | -49.1% | 14,097.8% | – |
| EPS Diluted | -1.37 | -0.89 | 0.071 | 0.042 |
| % Growth | -53.9% | -1,357.1% | 68.6% | – |
| Operating Cash Flow | -$92,167 | -$26,772 | -$102,543 | -$113,328 |
| Capital Expenditures | -$3,066 | -$3,924 | -$2,634 | -$16,908 |
| Free Cash Flow | -$95,233 | -$30,696 | -$105,177 | -$130,236 |